BioArctic AB (publ) BRCTF
Set alert
29.40 USD 0.00 0.00%
At close · Oct 29
35.00 Day range 35.00
27.82 52-week range 38.75
- YTD
- -15.37%
- 1 year
- -8.58%
- Open
- 35.00
- Prev close
- 29.40
- Mkt cap
- 2.61B
- Vol
- 250
- Avg vol
- 17
- EPS
- 0.13
- P/E
- 226.15
More statistics
- Low
- 35.00
- High
- 35.00
- Earnings
- Aug 26, 2026
Next earnings
Aug 26, 2026
Expected Aug 26, 2026. Consensus EPS estimate -0.0344.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 26, 2026 | Jun 30, 2026 | -0.0344 | — | — | — |
| May 20, 2026 | Mar 31, 2026 | -0.03156 | 0.2514 | +0.28 | +896.58% |
| Feb 18, 2026 | Dec 31, 2025 | -0.05843 | -0.01082 | +0.05 | +81.48% |
| Nov 13, 2025 | Sep 30, 2025 | -0.12126 | -0.10458 | +0.02 | +13.76% |
| Jun 30, 2025 | Jun 30, 2025 | 0.162 | 0.114 | -0.05 | -29.63% |
| Mar 31, 2025 | Mar 31, 2025 | 1.03 | 1.15 | +0.12 | +11.65% |
News
- BioArctic's Nomination Committee appointed
- Number of shares and votes in BioArctic AB (publ) as of August 31, 2026
- BioArctic AB (publ) (BRCTF) Q2 2026 Earnings Call Transcript
- BioArctic and Mesenkia enter oncology research collaboration
- Invitation to presentation of BioArctic's second quarter report for April - June 2026 on August 26 at 9:30 a.m. CEST
- More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026
- BioArctic and Lilly sign research and collaboration agreement combining Lilly compound with BioArctic's BrainTransporter™ technology
- Number of shares and votes in BioArctic AB (publ) as of May 29, 2026
- Bulletin from the Annual General Meeting in BioArctic AB (publ)
- BioArctic AB (publ) (BRCTF) Q1 2026 Earnings Call Transcript
Your note
Sign in to keep a note on BRCTF — it syncs with the Stock Master app.